The Impact of Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Body Composition, Strength, and Power in Collegiate Athletes

Original Research

Jeffery L. Heileson¹, Ashlyne Elliott², Julie A. Buzzard¹, Mitchell C. Cholewinski¹, Andrew Gallucci¹, LesLee K. Funderburk¹

¹Baylor University, Waco, TX/USA
²Veterans Health Administration, Houston, TX/USA

Abstract

Introduction: Recent evidence suggests that long-chain omega-3 polyunsaturated fatty acid (LC n-3) supplementation may enhance training adaptations associated with athletic performance. This study examined the impact of LC n-3 supplementation on body composition, strength, and power in collegiate athletes.

Methods: Athletes (n = 27) were assigned to one of two conditions for eight weeks: fish oil (FO, 3.0 g∙d⁻¹ [1.75g EPA and 1.1g DHA], n = 15) or placebo (PL, high-oleic safflower oil, 3g, n = 12) for 8-weeks. Athletes completed a three-day food log and questionnaire, provided a blood sample via fingerstick to determine their LC n-3 status, conducted body composition analysis through dual energy x-ray absorptiometry, and had their handgrip strength (HGS) and countermovement jump assessed.

Results: In the FO group, the omega-3 index, EPA and DHA increased by 73%, 332% and 64%, respectively, while there was no change in the placebo group. HGS significantly improved in the FO group (p = .018, +9.1%) and did not change in the placebo group (p = .615, -1.8%). Body composition and power were similar between groups. The change in HGS was positively correlated with the relative change in EPA and EPA:AA ratio.

Conclusions: For in-season athletes, the addition of LC n-3 supplementation to a dietary regime increases blood LC n-3 status and may preserve or improve muscular performance while in-season.

Key Words: athletic performance, eicosapentaenoic acid, docosahexaenoic acid

Corresponding author: LesLee K. Funderburk, leslee_funderburk@baylor.edu

Introduction

Long-chain omega-3 polyunsaturated fatty acids (LC n-3), primarily the bioactive constituents eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), are widely recognized for their cardio- and neuroprotective capabilities¹,² and have recently been associated with some aspects of athletic performance and recovery.³-⁵ The influence of LC n-3s on various physiological
conditions that limited training. The study was approved by the University’s Institutional Review Board and written informed consent was obtained from each participant.

Participants in the FO (1.75g EPA, 1.10g DHA) and PL (3g high-oleic safflower oil) groups were instructed to consume 5 soft gel capsules per day of their assigned supplement. The athletes were asked to take their supplement with a meal ± 1.5 y) collegiate athletes volunteered for the study (n = 14 males, n = 22 females). Twenty-seven (77%) completed the intervention. Athletes were recruited from the NCAA D1 teams, intramural clubs, and the university competitive dance team. All athletes volunteered for the study during their sports’ respective in-season. Participants were screened and excluded if they had any medical conditions that limited training. The study was approved by the University’s Institutional Review Board and written informed consent was obtained from each participant.

Three-day Food Record and Omega-3 Food Frequency Questionnaire
To assess macronutrient intake before and after the intervention, athletes tracked all calorie containing foods and beverages three days (two weekdays and one weekend) via a smartphone app (MyFitnessPal®). This mobile application has been validated as an effective method to measure self-reported dietary intake. Additionally, to specifically determine their habitual intake of omega-3 fatty acids, athletes were asked to complete a validated 21-item omega-3 FFQ. The FFQ quantifies the omega-3 intake from plant and marine sources based on the frequency and portion size consumed over the last day, week, and 6 months.

Supplementation Protocol
Participants in the FO (1.75g EPA, 1.10g DHA) and PL (3g high-oleic safflower oil) groups were instructed to consume 5 capsules per day of their assigned supplement. The athletes were asked to take their supplement with a meal...
containing fat, typically the evening meal, to maximize absorption. Participants were provided their supplements in two week increments. The FO supplementation contained a higher EPA dose than DHA, which was selected due to the pre-clinical data identifying EPA as the primary n-3 component involved in muscle protein turnover.\textsuperscript{28} Both the treatment and placebo products were produced from CAS BioSciences, LLC (New York USA / California USA). The FO and PL products used in this study were manufactured under the applicable US Food & Drug Administration Good Manufacturing Practices, and were packaged for this study by CAS BioSciences, LLC’s partner company, Gemini Pharmaceuticals, Inc. (New York USA), under US Food & Drug Administration 21 CFR Part 211 pharmaceutical standards.

**Body Composition**

Body mass was measured on a mechanical scale while the participant wore light, athletic clothing without shoes and their height was measured with a stadiometer (Seca 703, China). Body composition (LBM and fat mass [FM]) was estimated using the Dual Energy X-ray Absorptiometry (DXA, Discovery DXA™, Hologic®, Bedford, MA). The fat-free mass index (FFMI), a height adjusted measure of lean body and bone mass, was calculated by dividing the FFM by height squared\textsuperscript{26} and used for analysis.

**Strength and Power**

Handgrip strength (HGS) was measured using a dynamometer (Hydraulic Hand Dynamometer, Baseline® Evaluation Instruments) at baseline and at the end of the study. The participants were instructed to hold the dynamometer with their dominant arm with their elbow at a 90° angle and squeeze as hard as possible until the observer started to see a decrease in the reading. The width of the dynamometer was adjusted for each participant to ensure a firm grip. This was indicated by the phalanx positioned 90° while covering the handle. The attempt was recorded in kilograms and the gauge was reset. The athlete rested at least one minute between attempts. Participants were assessed on three separate attempts and the results were averaged for data analysis.

Vertical jump height was assessed by measuring countermovement jump (CMJ) using the VALD ForceDecks dual-force plates and the information was analyzed with the VALD ForceDecks software (Version 2.0.7782) at baseline and at the end of the study. Peak (PP) and mean power (MP) were calculated from body mass (kg) and jump height (cm) using validated formulas.\textsuperscript{27,28} All athletes conducted CMJ on a regular basis for internal testing, hence, the familiarization session was just prior to the first measure to standardize the process. The participants were instructed to conduct the CMJ with hands on hips to eliminate upper limb technique. The jumps were performed three times allowing for a standard one-minute rest interval in-between each jump. The average of the three attempts were used for data analysis.

**Blood Fatty Acid Analysis**

A drop of blood was collected from each participant via finger stick on filter paper pre-treated with a cocktail solution (Fatty Acid Preservative Solution, FAPS™) and allowed to dry at room temperature for 15 min. The dried blood spots (DBS) were shipped to OmegaQuant for fatty acid analysis. Fatty acids were identified by comparison with a standard mixture of fatty acids characteristic of RBC (GLC OQ-A, NuCheck Prep, Elysian, MN) which was also used to construct individual fatty acid calibration curves. Fatty acid composition was expressed as a percent of total identified fatty acids. The O3i is defined as the sum of EPA and DHA adjusted by a regression equation ($r = 0.96$) to predict the O3i in the RBC.

**Statistical Analysis**

Data reported as means and standard deviations. Relative and absolute change scores are reported as mean and 95% confidence intervals (lower bound, upper bound). Baseline and dependent variables with change scores, and percent changes were assessed for group differences via a $t$-test. After determining data normality and homogeneity of variance using the Shapiro-Wilks and Levene’s Test for Equality of Variances, a mixed model repeated measures ANOVA was used to determine if interactions between group and time occurred for body composition, strength, or power. For significant findings, multiple comparison testing was performed using a Bonferroni adjustment. Between group differences were further analyzed using effect sizes (Cohen’s $d$). The effect sizes (ES) were classified as follows: $< 0.20$, trivial; $0.20$–$0.49$, small; $0.50$–$0.79$, moderate; $\geq 0.80$, large.\textsuperscript{29} Pearson correlations were used to examine the relationship between whole blood fatty acids and changes in strength and power. Data were analyzed using SPSS version 27 (IBM SPSS, Chicago, IL). Significance was set $a$ priori at $p < .05$. Based on the various performance metrics in a similar population, we estimated that our sample size should be between 24 and 32 athletes ($f = 0.26$–$0.30$, $1 - \beta = 0.80$, $\alpha = 0.05$).\textsuperscript{10}
Results

Participants

Of the 36 athletes randomized to a group, 27 (77%) completed the intervention. Of the 9 dropouts, 4 from the FO group and 5 from the PL group, 8 were due to >2 missed supplement distributions and one dropout in the FO group was due to nausea attributed to the intervention. The athletes that completed the study were from track and field (n = 6), baseball/softball (n = 5), spirit team (n = 11), volleyball (n = 2), crew (n = 2), and acrobatics and tumbling (n = 1). All athletes underwent body composition analysis (n = 27); however, only partial data were available for whole blood fatty acid analysis (n = 20), HGS (n = 14), CMJ (n = 25), FFQs (n = 19) and dietary logs (n = 12). There were no group differences for participant age (p = .972), body mass (p = .519), or height (p = .335).

Dietary Intake

There were no group differences at baseline for any macronutrient (p > .05). From PRE to POST, dietary intake of calories (p = .952), protein (p = .424), carbohydrates (p = .894) and fat (p = .629) were unchanged. There were no group by time differences in dietary intake of calories (p = .467), fat (p = .436), protein (p = .997), or carbohydrate (p = .655). From PRE to POST, dietary intake of EPA (p = .770), DHA (p = .286), and ALA (p = .903) were similar between groups.

Omega-3 Index and Whole Blood Omega-3 Fatty Acids

Pre-supplementation O3i and whole blood fatty acids were similar between groups. Figure 1 shows the individualized changes of the O3i from PRE to POST in each group. In the PL group, the O3i (4.67% to 4.52%; p = .731), whole blood EPA (0.37% to 0.33%; p = .852), DHA (2.62% to 2.49%; p = .549), and AA (10.50% to 10.75%; p = .335) were similar from PRE to POST. In the FO group, the O3i (4.58% to 7.94%; p < .001), whole blood EPA (0.41% to 1.77%; p < .001) and DHA (2.46% to 4.04%; p < .001) significantly increased, while AA (10.74% to 10.00%; p = .029) decreased.

Figure 1. Individual changes in the Omega-3 Index in the fish oil (n = 12) and placebo (n = 8) groups. Values <4 are high-risk and values >8 are low-risk for cardiovascular disease. *indicates a significant difference compared to baseline and between groups (p < .001).

Body Composition

At baseline, there were no significant group differences in weight, LBM, FFMI, FM, or %BF. Table 1 shows the PRE, POST, and change values of weight, LBM, FFMI, FM, and %BF for each group. Briefly, body composition changes were similar between groups (p > .05). The between group effect sizes indicated small differences between LBM (ES = 0.21), FM (ES = 0.38), and %BF (ES = 0.47).
Whole Blood Fatty Acids and Strength and Power

Relationship between Whole Blood Fatty Acids and Strength and Power

The percent change of whole blood EPA (\(r = 0.874, p = .005\)) and EPA:AA (\(r = 0.849, p = .008\)) was positively and strongly correlated with HGS. However, EPA and EPA:AA was not associated with the change in CMJ height (\(r = 0.144, p = .569, r = 0.084, p = .740\), respectively), PP (\(r = -0.135, p = .594, r = -0.182, p = .469\), respectively), or MP (\(r = 0.105, p = .679, r = 0.078, p = .758\), respectively). The percent change of DHA or DHA:AA was not correlated with any performance outcome (\(p > .05\)).
Discussion
The primary aim of this study was to investigate the effect of fish oil supplementation (2.85g\textsuperscript{-1} EPA+DHA) for 8-weeks on body composition, strength, and power in collegiate athletes. We demonstrated that LC n-3 supplementation increases HGS and that the relative changes in HGS were positively correlated with the change in whole blood EPA and the EPA:AA ratio. Our results also indicate that LC n-3 supplementation tends to confer favorable effects on body composition and power; however, this relationship is less clear.

We found that LC n-3 supplementation improved HGS in athletes by 3.1 kg (9.1%) over 8-weeks. With or without resistance training, previous trials have reported increases in HGS with LC n-3 supplementation.\textsuperscript{30–32} Using a similar daily dose of EPA+DHA, Lee et al.\textsuperscript{30} reported that HGS increased by 2.5 kg (9.4%) in combination with resistance training, which was 1.0 kg (4.1%) and 3.5 kg (13.3%) higher than in the resistance training only and control group, respectively. Compared to PL, Smith et al.\textsuperscript{31} reported that FO supplementation improved HGS by 2.3 kg (~6.5%).

Conversely, trials providing less potent FO doses do not report beneficial effects on HGS.\textsuperscript{33,34} While we provided 2.85g\textsuperscript{-1} LC n-3 and reported a significant improvement in HGS, our study was the first to demonstrate these findings in young athletes. Notably, Gravina et al.\textsuperscript{35} found that LC n-3 supplementation (0.1g\textsuperscript{-1} kg, 6.3 ± 1.8g\textsuperscript{-1}), in elite soccer players, did not increase 1RM leg extension compared to PL. Although speculative, one plausible explanation for the divergent findings may be that we opted for a field expedient isometric measure compared to a more common 1RM assessment. Previous studies have reported that LC n-3 supplementation may not improve 1RM, but improves isometric strength, which suggests that the effects of LC n-3 are related to muscular, not neural, adaptations.\textsuperscript{36,37} It should be noted that a recent trial, in contrast to Gravina et al., demonstrated that healthy young adults taking 1.4 g\textsuperscript{-1} LC n-3 for 4 weeks significantly improved 1RM leg extension (+14.1 kg), whereas there was no improvement in the PL group.\textsuperscript{38} Interestingly, we noted that the relative change in EPA and EPA:AA was significantly correlated to the change in HGS, while DHA and DHA:AA were not correlated. Our results align with recent studies showing that upper body strength was associated with plasma and whole blood EPA and EPA:AA.\textsuperscript{16,22}

In the FO group, CMJ height increased by 2.2%, while CMJ decreased by 1.1% in the PL group. Notably, the difference was not significant from PRE to POST or between groups, despite the magnitude being indicative of a moderate effect (ES = 0.54). From a practical standpoint, the minimal improvement (< 1 cm) and decline (< 1 cm) in CMJ height between the FO and PL group, respectively, may not have a meaningful impact on sport performance. In elite rugby players, Black et al.\textsuperscript{39} reported that LC n-3 supplementation (1.1 g\textsuperscript{-1} EPA+DHA) for 5 weeks improved CMJ performance by 4.6%, whereas CMJ decreased by 3.4% in the PL group. It is unclear why the magnitude of improvement and decline in the FO and PL group, respectively, was much greater compared to our study. This result may be partially explained by the mixed group of athletes in our sample experiencing different training routines compared to rugby players in a homogeneous training environment.

For in-season athletes, we also demonstrated that FO supplementation led to a 0.7 kg increase in LBM and a 0.1 kg loss of FM, whereas LBM and FM increased by 0.3 kg and 0.4 kg in the PL group, respectively. While the results were not significant, the body composition changes observed in the FO group were remarkably similar to those reported in previous studies.\textsuperscript{31,32,40–42} In regards to LBM, two studies in young, healthy adults have reported increases in LBM ranging from 0.2 kg to 0.5 kg with LC n-3 supplementation.\textsuperscript{40,42} Utilizing a similar LC n-3 dose as our study (2.4g\textsuperscript{-1} EPA+DHA), Noreen et al.\textsuperscript{40} reported that FO significantly increased LBM by 0.5 kg over 6 weeks. While Couet et al.\textsuperscript{42} reported an 0.2 kg increase in LBM, the results were not significantly different than the control condition. One plausible explanation for the magnitude of effect differences may be related to the LC n-3 dose provided. Our study and that of Noreen et al.\textsuperscript{40} supplied > 2g\textsuperscript{-1} LC n-3, whereas Couet et al.\textsuperscript{42} only provided 1.8 g\textsuperscript{-1} LC n-3 over three weeks. Evidence in clinical populations tend to agree with the implication that ≥ 2g LC n-3 per day may be needed to elicit a meaningful increase in LBM.\textsuperscript{31,32} Both trials also reported significant decreases in FM between the FO and PL groups with treatment effects of 0.58 and 0.7 kg.\textsuperscript{40,42} Although our study reported similar results, the between group difference was less than previously reported (0.5 kg). While the data appear to be directionally consistent with other studies in young, healthy adults, our investigation was unable to definitively show a beneficial effect of FO supplementation on body composition.

Our study was not without limitations that should be considered when interpreting our results. First, we did not track physical activity during the intervention; however, athletes participated in their regular training regimes and were all in the same phase of training (in-season). As the athletes were recruited from various sports, some of the differences between outcomes could be influenced by the markedly different training regimes based on sport. Due to contact precautions established to protect the safety of the athletes during the pandemic, the DXA protocol was...
unstandardized and there was incomplete data collection. Lastly, our sample size did not allow us to compare or assess differences in outcome measures between sports. While our findings may be generalized to athletes, individual recommendations based on sport are much more tenuous.

Conclusions
In the context of in-season training, 8-weeks of LC n-3 supplementation (2.9g·d⁻¹) increases HGS in collegiate athletes and the degree of improvement is positively correlated with the increase in whole blood EPA and EPA:AA. Although we reported favorable outcomes for power and body composition in athletes taking a FO supplement, the results were less conclusive and must be interpreted with caution. Given the recently reported depletion of EPA and DHA status during physical training and the sub-optimal LC n-3 status in athletes, fish oil supplementation sustained over time has the potential to positively impact athletic performance.

Acknowledgements
The authors would like to thank the wellness and athletic staff and athletes for their willingness to participate in the study. Additionally, we’d like to thank CAS BioSciences for their generous donation of the fish oil and placebo supplements.

References
Oil consumption with resistance training improves grip strength, 2019;33(10):2622


